BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 12556100)

  • 21. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University.
    Steiner E; Eicher O; Sagemüller J; Schmidt M; Pilch H; Tanner B; Hengstler JG; Hofmann M; Knapstein PG
    Int J Gynecol Cancer; 2003; 13(2):197-203. PubMed ID: 12657124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FIGO staging of endometrial cancer: 2023.
    Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
    Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
    Korshunov A; Golanov A
    Arch Pathol Lab Med; 2001 Jul; 125(7):892-8. PubMed ID: 11419973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
    Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
    Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parametrial spread is a prognostic factor in endometrial carcinoma.
    Sato R; Jobo T; Kuramoto H
    Eur J Gynaecol Oncol; 2003; 24(3-4):241-5. PubMed ID: 12807232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 1999 Dec; 75(3):432-6. PubMed ID: 10600302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki-S1--a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy.
    Kuropkat C; Rudolph P; Parwaresch R; Werner JA
    Anticancer Res; 2003; 23(5A):3965-70. PubMed ID: 14666704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between Morphological Patterns of Myometrial Invasion and Cancer Stem Cell Markers in Endometrial Endometrioid Carcinoma.
    Park JY; Hong D; Park JY
    Pathol Oncol Res; 2019 Jan; 25(1):123-130. PubMed ID: 28990139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma.
    Liu S; Lin M; Ji H; Ding J; Zhu J; Ma R; Meng F
    Diagn Pathol; 2019 Jan; 14(1):7. PubMed ID: 30684972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The value of Ki-67 antigen expression in tissue microarray method in prediction prognosis of patients with endometrioid endometrial cancer].
    Gottwald L; Kubiak R; Sek P; Piekarski J; Szwalski J; Pasz-Walczak G; Spych M; Suzin J; Tylińskis W; Jeziorski A
    Ginekol Pol; 2013 Jun; 84(6):444-9. PubMed ID: 24032262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study.
    Zannoni GF; Vellone VG; Arena V; Prisco MG; Scambia G; Carbone A; Gallo D
    Virchows Arch; 2010 Jul; 457(1):27-34. PubMed ID: 20552366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
    Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
    J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
    Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
    Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
    Ghoniem K; Larish AM; Dinoi G; Zhou XC; Alhilli M; Wallace S; Wohlmuth C; Baiocchi G; Tokgozoglu N; Raspagliesi F; Buda A; Zanagnolo V; Zapardiel I; Jagasia N; Giuntoli R; Glickman A; Peiretti M; Lanner M; Chacon E; Di Guilmi J; Pereira A; Laas E; Fishman A; Nitschmann CC; Parker S; Joehlin-Price A; Lees B; Covens A; De Brot L; Taskiran C; Bogani G; Paniga C; Multinu F; Hernandez-Gutierrez A; Weaver AL; McGree ME; Mariani A
    Gynecol Oncol; 2021 Sep; 162(3):590-598. PubMed ID: 34274133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.
    Chattopadhyay S; Cross P; Nayar A; Galaal K; Naik R
    Int J Gynecol Cancer; 2013 May; 23(4):690-7. PubMed ID: 23518862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic parameters in FIGO stage I endometrial carcinoma of endometrioid type].
    Stanojević Z; Dordević B
    Vojnosanit Pregl; 2006 Dec; 63(12):1006-10. PubMed ID: 17252704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival.
    Geisler JP; Geisler HE; Manahan KJ; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Int J Gynecol Cancer; 2004; 14(1):133-7. PubMed ID: 14764041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.